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ABSTRACT
Introduction. Non-clinical evaluation of a medication’s potential to induce cardiac toxicity is recommended by
regulatory agencies. 4-Aminopyridine (fampridine) is a potassium channel blocker with the demonstrated ability to
improve walking ability in patients with multiple sclerosis. We evaluated the in vitro effects of 4-aminopyridine on
the human ether-à-go-go-related gene (hERG) channel current, since hERG current inhibition is associated with QT
interval prolongation—a precursor to torsade de pointes (TdP).
Methods. 4-Aminopyridine was evaluated in concentrations ranging from 0.1 mM to 30 mM in human embryonic
kidney 293 cells stably transfected with the hERG gene; terfenadine 60 nM was used as a positive control.
Results and Discussion. We observed concentration-dependent inhibition of hERG current with 4-aminopyridine
doses between 0.3 and 30 mM. The concentration of 3.8 mM resulting in 50% inhibition (IC50) is approximately
three orders of magnitude higher than expected therapeutic plasma concentrations, suggesting 4-aminopyridine has
low potential for prolonging QT interval or inducing TdP.
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Introduction
4
-Aminopyridine (fampridine) is a potassium
channel blocker that has been evaluated for the
improvement of walking ability in patients with
multiple sclerosis (MS). Several studies have dem-
onstrated that 4-aminopyridine has the ability to
signiﬁcantly improve lower extremity strength and
walking speed, relative to placebo, in a proportion
of patients with MS [1–4]. At millimolar concen-
trations, 4-aminopyridine is a broad-spectrum
blocker of potassium channels, as has been
demonstrated in laboratory studies [5,6]. Typical
plasma concentrations that are obtained during
clinical studies, however, fall into a lower range of
less than 1 mM (94 ng/mL). The characteristics of
potassium channels that are blocked at these low
concentrations have not yet been determined. The
neurological effects of the compound, however,
are consistent with potassium channel blockade.
Although an assessment of the general safety of
a therapeutic agent is incorporated into clinical
trials, the potential for cardiac toxicity is a distinct
concern that requires independent evaluation.
This concern arises primarily from the ability of
some non–anti-arrhythmic drugs to delay cardiac
repolarization—an undesirable characteristic that
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fatal cardiac arrhythmias as torsade de pointes
(TdP) [7,8].
Since TdP is almost always preceded by prolon-
gation of the cardiac QT interval, QT interval
prolongation is recognized as a surrogate marker
for pro-arrhythmic risk [7,9]. Prolongation of the
QT interval has been associated with the induction
of TdP across a broad range of non-cardiac drugs
[7,10]. Consequently, clinical assessment of the
potential for QT interval prolongation is now part
of the drug evaluation process required by the US
Food and Drug Administration (FDA) for new
drugs and for approved drugs when new indica-
tions, dosages, or routes of administration are
introduced [9]. However, since prolongation of the
QT interval is considered a less-than-optimal
marker of cardiac risk [7,9], it has been addition-
ally recommended that the potential cardiac toxi-
city of a drug be evaluated using non-clinical
systems [11].
The rapid delayed rectiﬁer potassium current
(IKr), of which the major channel protein is
encoded by the human ether-à-go-go-related gene
(hERG; KV11.1), is responsible for repolarization
of the cardiac myocyte ventricular action potential
[8,12,13]. Although moderate blockade of IKr
results in the beneﬁcial anti-arrhythmic effects of
some cardiac drugs, inhibition of IKr is the most
common cause of cardiac action potential prolon-
gation by non-cardiac drugs leading to the devel-
opment of TdP [10,14,15]. Whereas most, but not
all, of the drugs associated with induction of TdP
have also been shown to inhibit hERG channels
[10,16], those that do inhibit these channels gen-
erally do so at concentrations that approximate
therapeutic plasma levels [10].
The ability of human embryonic kidney 293
(HEK293) cells stably transfected with the hERG
gene to produce a current analogous to IKr [17]
provides a reliable model for the in vitro evalua-
tion of drugs for inhibition of IKr. This model has
been accepted as part of the non-clinical evalua-
tion of a drug’s potential for pro-arrhythmic
effects [11,18].
Although a generally favorable safety proﬁle has
been reported for 4-aminopyridine in clinical trials
[1–4], since the agent is a potassium channel
blocker, it is important to determine its potential
for cardiac toxicity through inhibition of the
hERG potassium channel. The purpose of this
study was to evaluate the in vitro effects of
4-aminopyridine on the hERG channel currents in
a stably transfected human cell line.
Methods
This study was conducted in accordance with
Good Laboratory Practice Standards. All chemi-
cals were obtained from Sigma-Aldrich (St. Louis,
Missouri, USA.) unless noted otherwise.
Cell Cultures
The cardiac potassium channel hERG gene was
transfected into HEK293 cells (American Type
Culture Collection, Manassas, Virginia, USA), an
HEK cell line. This cell line was maintained at a
low passage number (<50) at 37°C under 95%
O2/5% CO2 atmosphere in Dulbecco’s Modiﬁed
Eagle’s Medium/Nutrient Mixture F-12 (Invitro-
gen Corporation, Carlsbad, California, USA)
supplemented with 10% fetal bovine serum (Invit-
rogen Corporation, Carlsbad, California, USA),
100 U/mL penicillin G sodium (Invitrogen
Corporation, Carlsbad, California, USA), and
100 mg/mL streptomycin sulfate (Invitrogen Cor-
poration, Carlsbad, California, USA); cell stocks
were maintained in cryogenic storage. Trans-
fection was performed using an adenovirus 5
plasmid–containing human hERG cDNA and the
G418-resistance gene; 100 mg/mL G418 was
added to the incubation medium after transfection
to facilitate selection of stable colonies. Cells used
for electrophysiology were plated in plastic culture
dishes.
Chemicals and Reagents
Test compounds included 4-aminopyridine
(99.6% purity; obtained from Elan Pharma Ltd.,
Athlone, Ireland), terfenadine as a positive control,
and the reference compound E-4031 (N-[4-
[[1-[2-(6-methyl-2-pyridinyl)ethyl]-4-piperidinyl]
carbonyl]phenyl] methanesulfonamide dihydro-
chloride), a high-afﬁnity selective hERG blocker
[8] that was used to subtract non-hERG current
from each patch-clamp recording. Stock solutions
of 4-aminopyridine were prepared in distilled
water; stock solutions of terfenadine and the refer-
ence compound were prepared in dimethyl sulfo-
xide (DMSO) and stored frozen until use. Test
formulations were prepared by dilution of stock
solutions into a HEPES-buffered physiological
saline(HB-PS)composedof137 mMNaCl,4 mM
KCl, 1.8 mM CaCL2, 1 mM MgCl2,1 0 m M
HEPES, and 10 mM glucose, pH-adjusted to 7.4
with NaOH. Since DMSO at concentrations up to
0.3%doesnotaffecthERGchannelcurrents(Data
on ﬁle, ChanTest Corporation), test solutions of
the positive control and the reference substance
52 Renganathan et al.
Arch Drug Info 2009;2:51–57contained 0.3% DMSO. Pipette solution for
whole-cell recordings was composed of 130 mM
potassium aspartate, 5 mM MgCl2, 5 mM EGTA
(ethylene glycol tetraacetic acid), 4 mM ATP
(adenosine triphosphate), and 10 mM HEPES,
pH-adjusted to 7.2 with KOH. The pipette solu-
tion was prepared in batches, stored frozen at
-80°C, and a fresh aliquot thawed each day.
Electrophysiological Measurements
All experiments were performed at near-
physiological temperature (35  2°C), which was
maintained using a combination of in-line solution
heater, chamber ﬂoor heater, and feedback tem-
perature controller, with the temperature mea-
sured using a thermistor probe immersed directly
into a recording chamber. Patch pipettes were
made from borosilicate glass capillary tubing using
a P-97 micropipette puller (Sutter Instruments,
Novato, California, USA). The pipette resistance
was within the range of 2–5 MW. A commercial
patch clamp ampliﬁer was used for whole-cell
recordings. Before digitization, records were low-
pass ﬁltered at one-ﬁfth of the sampling frequency.
Data acquisition and analysis were performed
using pCLAMP software (version 8.2; Axon
Instruments, Union City, California, USA).
Evaluation of 4-aminopyridine was conducted
in two phases. The ﬁrst phase was designed to
identify the approximate concentration range
and the second phase to determine the precise
concentration-response relationship. In both
phases, the onset and steady-state block of hERG
channel currents were measured using a voltage
protocol consisting of a 1-sec conditioning step to
+20 mV, immediately followed by a repolarization
test ramp (from +20 mV to -80 mV at 0.5 mV/
second) applied at 5-second intervals from a
holding potential of -80 mV.
For each experiment, cells were transferred to
the recording chamber and superfused with
HB-PS. Peak test pulse current was measured
during the test ramp, and steady state was main-
tained for at least 20 second prior to application of
4-aminopyridine or the positive control. Peak
current was measured until a new steady state was
achieved. Each recording ended with a ﬁnal appli-
cation of a supramaximal concentration (500 nM)
of the reference compound to assess the contribu-
tion of endogenous currents. The remaining
unblocked current was digitally subtracted from
all current traces to determine the potency of
4-aminopyridine for hERG current inhibition.
The range of concentrations tested was 0.1–
30 mM. Vehicle control and positive control
experiments each were performed in three cells.
Steady state was deﬁned by the limiting constant
rate of change with time, and steady state before
and after each 4-aminopyridine application was
used to calculate the proportion (%) of current
inhibited at each concentration.
Data Analysis
Concentration-response data were ﬁtted to the
following equation:
%Inhibition
concentration IC =− + [] () [] {} ⋅ 1 1 1 100 50
n
% Inhibition represents the proportion of hERG
current inhibited at each concentration, IC50 is the
concentration resulting in 50% inhibition, and n is
the Hill coefﬁcient. Non-linear least squares ﬁts
were performed with the Solver add-in for Excel
2000 (Microsoft Corporation, Seattle, Washing-
ton, USA) and the IC50 was calculated.
Results
Typical hERG voltage-clamp current traces
acquired in control, after equilibration with
4-aminopyridine (1 mM), and after application of
the reference compound E-4031 are illustrated in
Figure 1a. Following activation by the condition-
ing prepulse, repolarization to -80 mV evoked a
large, slowly decaying outward current, which was
reduced with the application of 4-aminopyridine.
The corresponding time course of the peak hERG
current in control, and after applications of
4-aminopyridine and the reference substance, is
shown in Figure 1b.
As demonstrated in the experimental data,
4-aminopyridine induced a concentration-
dependent inhibition of the hERG channel cur-
rents. The mean percentage of current inhibited at
each 4-aminopyridine concentration is presented
in Table 1. The means (standard deviation)
for 4-aminopyridine concentrations of 0.3 mM,
1 mM, 10 mM, and 30 mM were 8.2  0.9%
(N = 3), 31.8  3.8% (N = 4), 67.6  3.6%
(N = 4), and 76.7  3.1% (N = 3), respectively.
The concentration-response relationship for this
effect is depicted in Figure 2. At the two lowest
concentrations, 0.1 mM had no effect and inhibi-
tion of hERG by 4-aminopyridine 0.3 mM was
minimal (8.2  0.9%; N = 3). Increasing concen-
trations of 4-aminopyridine resulted in greater
inhibition, with an estimated IC50 of 3.83 mM and
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4-aminopyridine, steady state was reached within
1–1.5 minutes. For 10 and 30 mM, steady state
was reached within 30 seconds. No steady state
inhibition was reported for 0.1 mM since it had no
inhibitory effect. Terfenadine, at a concentration
of 60 nM, inhibited 82.8  2.4% of the current
(mean  standard error; N = 3), conﬁrming sensi-
tivity of the test system to hERG inhibition.
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Figure 1 Sample traces of hERG current in the absence and presence of 4-aminopyridine (a), and during the time course
of 4-aminopyridine evaluation (b). Measurements were performed at 35  2°C using a voltage protocol consisting of a 1-sec
conditioning step to +20 mV, followed by a repolarization test ramp (from +20 mV to -80 mV at 0.5 mV/s) applied at 5-s
intervals from a holding potential of -80 mV.
Table 1 4-Aminopyridine inhibition of hERG, expressed
in stably transfected human embryonic kidney cells
4-Aminopyridine concentration, mM
(number of replicates)
Mean percent inhibition
(standard deviation)
0 (3) 0.3 (0.1)
0.1 (2) 0.3 (0.3)
0.3 (3) 8.2 (0.9)
1 (4) 31.8 (3.8)
10 (4) 67.6 (3.6)
30 (3) 76.7 (3.1)
Figure 2 Concentration-dependent
inhibition of hERG current by 4-
aminopyridine. Numbers in parenthe-
ses indicate the number of
replicates.
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This study used in vitro expression of hERG in a
human cell line as a model for evaluating the
effects of 4-aminopyridine on IKr. This system has
become a standard for non-clinical evaluation of
the potential for QT interval prolongation [11,18],
and the validity of the assay system in the current
study was demonstrated by the positive control,
terfenadine, which at a concentration of 60 nM
resulted in approximately 82% inhibition. This
high rate of inhibition is consistent with the hERG
inhibition proﬁle of terfenadine [16].
The data obtained with this system show that
whereas 4-aminopyridine 0.1 mM has a negligible
effect on hERG current, concentration-dependent
inhibition occurs within the range of 0.3–30 mM.
The calculated values for 4-aminopyridine with an
IC50 of 3.83 mM and a Hill coefﬁcient of 0.69 are
comparable to those of 4.4 mM and 0.7, respec-
tively, that have been reported by Ridley and col-
leagues using a similar assay system [19].
Although inhibition of hERG by 4-
aminopyridine was observed, the clinical relevance
of these data needs to be considered. A review of
100 pharmacological agents associated with induc-
tion of TdP reported that in general, drugs that
present a risk for induction of TdP also inhibit
hERG at concentrations close to those achieved in
plasma during therapeutic administration [10]. A
safety margin of at least 30-fold between the IC50
for hERG inhibition and the maximum plasma
concentration achieved in clinical practice has
been suggested as being adequate for predicting
the safety of a drug with respect to risk for ven-
tricular arrhythmias [10].
For 4-aminopyridine, the IC50 of 3.83 mM is
several orders of magnitude higher than the
maximum plasma concentrations that have been
reported even at supratherapeutic doses. In a dose-
ranging study of fampridine sustained-release
(fampridine-SR) in patients with MS, which
included a pharmacokinetic analysis, the therapeu-
tic dose of 10 mg twice daily resulted in mean
steady-state plasma concentrations of 0.243 
0.113 mM[2],whichis4ordersofmagnitudelower
than the IC50 for hERG. Even at the highest dose
evaluated at 40 mg twice daily, the mean steady-
state plasma concentration was 0.97 mM. Similarly,
a study designed to evaluate the steady-state
pharmacokinetics of fampridine-SR in patients
with chronic spinal cord injury reported a mean
maximum plasma concentration of 0.639 
0.160 mM with a 20-mg dose administered twice
daily and 0.342  0.095 mM with a 10-mg dose
administered twice daily [20].
This greater than 4-log difference between the
IC50 and therapeutic plasma concentrations sug-
gests that the use of 4-aminopyridine is unlikely
to result in QT prolongation and induction of
TdP. However, the relationship of drug-mediated
inhibition of hERG and the risk of TdP may be
problematic. Nevertheless, the clinical risk for
drug-induced arrhythmia and sudden death may
be low, based on an analysis of adverse reactions
of drugs with known anti-hERG activity, which
showed that the higher the log of the ratio
between therapeutic concentrations and the IC50,
the lower the risk for cardiac adverse events [21].
However, an important consideration is that
there may be individuals who achieve higher
than expected peak plasma concentrations due to
impaired metabolism, elimination, or overdosage.
For perspective, a case report of substantial
4-aminopyridine overdose due to ingestion of
2–4 g resulted in plasma concentrations of 3.5 uM
[22]. While such a high plasma concentration
results in neurologic toxicity including seizure, it
is still 3 orders of magnitude lower than the IC50
for hERG reported here.
These data suggest an electrophysiological basis
for previous observations of a low risk of clinically
signiﬁcant cardiac effects associated with 4-
aminopyridine. Clinical studies that have incorpo-
rated electrocardiogram (ECG) evaluation as a
safety parameter reported no changes or trends in
ECG values [2,20,23]. Additionally, in a study that
evaluated the effects of a 1-month treatment
regimen with 4-aminopyridine on cardiac param-
eters in patients with spinal cord injury, the cardiac
parameters measured remained within normal
range compared with literature-derived control
values, and no evidence of QT prolongation was
observed [24].
Although 4-aminopyridine exhibits dose-
dependent inhibition of the hERG channel
current, the calculated IC50 is approximately four
orders of magnitude higher than reported thera-
peutic plasma concentrations. This difference
suggests a margin of safety that may confer low
torsadogenic potential based on the degree of IKr
inhibition we observed. However, while IKr inhibi-
tion does play a prominent role in drug-induced
TdP, which is the basis for the acceptance of
hERG inhibition as an indicator of potential
cardiac toxicity, it is important to recognize that
the effects of drugs on other ion channels, such as
increasing the plateau generated by sodium or
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currents, may also contribute to drug-induced QT
prolongation.
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